Online inquiry

IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12679MR)

This product GTTS-WQ12679MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FZD1&FZD2&FZD5&FZD7&FZD8 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003505.2; NM_001466.4; NM_003468.4; NM_003507; NM_031866.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8321; 2535; 7855; 8324; 8325
UniProt ID Q9UP38; Q14332; Q13467; O75084; Q9H461
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12679MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10493MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY-2951742
GTTS-WQ9461MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IPH4102
GTTS-WQ115MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 11F8
GTTS-WQ12566MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NV-02
GTTS-WQ8205MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ10969MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ479MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ791MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Ab-2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW